Enlivex Therapeutics Ltd.
Tel Aviv Stock Exchange ENLV.TA
Enlivex Therapeutics Ltd. Market Capitalization on January 14, 2025: USD 25.48 M
Enlivex Therapeutics Ltd. Market Capitalization is USD 25.48 M on January 14, 2025, a -58.53% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
-
Enlivex Therapeutics Ltd. 52-week high Market Capitalization is USD 90.10 M on March 13, 2024, which is 253.55% above the current Market Capitalization.
-
Enlivex Therapeutics Ltd. 52-week low Market Capitalization is USD 21.09 M on November 24, 2024, which is -17.24% below the current Market Capitalization.
-
Enlivex Therapeutics Ltd. average Market Capitalization for the last 52 weeks is USD 37.53 M.
Key data
| Date | Market Capitalization | Share Price | Price to Earnings Ratio (P/E) | Price to Sales Ratio (P/S) |
|---|
Market news
Loading...
Tel Aviv Stock Exchange: ENLV.TA
| CEO | Dr. Oren Hershkovitz Ph.D. |
| IPO Date | July 22, 2019 |
| Location | Israel |
| Headquarters | 14 Einstein Street |
| Employees | 77 |
| Sector | Health Care |
| Industries | |
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email